{"ticker": {"uuid": "1627bf3d-c02b-40f2-9309-b63521098f72", "symbol": "PCSA", "name": "Processa Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Processa Pharma (PCSA) Stock Analysis Report | Financials & Insights", "summary": "This report provides a stock analysis for Processa Pharma (PCSA), a clinical-stage biopharmaceutical company focusing on Next Generation Chemotherapy oncology drug products. It covers the company's general information, how it's graded based on various financial metrics, peer comp", "url": "https://es.benzinga.com/quote/PCSA/report", "source_name": "Benzinga Espa\u00f1a", "published_at": "2026-07-04T07:11:56", "published_display": "04 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL", "summary": "This article is a statement of changes in beneficial ownership of securities for Officer SKIBSTED RUSSELL at Processa Pharmaceuticals. It indicates a filing of Form Type 4, which is used to report changes in ownership of company stock by insiders. The article details the specific", "url": "https://www.moomoo.com/news/notice/307647847/processa-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-03T19:12:07", "published_display": "03 Jul 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PROCESSA PHARMACEUTICALS INC. For: Jun 03 Filed: Jun 06", "summary": "This document, filed by PROCESSA PHARMACEUTICALS INC. on June 6 for the date June 3, is a statement of changes in beneficial ownership of securities. It specifically details changes for Officer Ng George K.", "url": "https://www.moomoo.com/news/notice/307647870/processa-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-03T19:12:07", "published_display": "03 Jul 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Lin Patrick", "summary": "This document reports a statement of changes in beneficial ownership of securities for Officer Lin Patrick of Processa Pharmaceuticals. It is filed as a Form 4, indicating transactions related to his holdings in the company.", "url": "https://www.moomoo.com/news/notice/307647882/processa-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-02T18:12:09", "published_display": "02 Jul 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) director buys 2,531 shares in open market", "summary": "Processa Pharmaceuticals (PCSA) director David Young purchased 2,531 shares of common stock at $1.93 per share in an open-market transaction on June 30, 2026. This acquisition increases his direct holdings to 21,729 shares. Young also reported indirect ownership through several e", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-0a411d1abcf2.html", "source_name": "Stock Titan", "published_at": "2026-07-02T04:39:21", "published_display": "02 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock By Investing.com", "summary": "Processa Pharmaceuticals CEO George Ng recently acquired 3,057 shares of the company's common stock for $5,900. This transaction increases his direct holdings to 15,492 shares, in addition to indirect holdings. The purchase occurred while PCSA stock is trading near its 52-week lo", "url": "https://ca.investing.com/news/stock-market-news/processa-pharmaceuticals-ceo-george-ng-acquires-5900-in-stock-93CH-4716992", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:39:21", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) CEO adds 3,057 shares in open-market buy", "summary": "Processa Pharmaceuticals (PCSA) CEO George K. Ng purchased 3,057 shares of Common Stock in an open-market transaction at $1.93 per share on July 1, 2026. Following this transaction, Ng directly owns 15,492 shares, with additional indirect holdings through related entities. The pu", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-6e53c2c846cf.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:21", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider purchase: Processa (NASDAQ: PCSA) CAO adds 2,436 shares in open-market buy", "summary": "Processa Pharmaceuticals' Chief Administrative Officer Guy Wendy recently purchased 2,436 shares of common stock at $1.93 per share in an open-market transaction. Following this purchase, Wendy directly holds 14,394 shares and indirectly owns 333 shares through CorLyst, LLC. This", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-854481868d0c.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:21", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CFO of Processa (NASDAQ: PCSA) adds 3,277 shares in open-market buy", "summary": "Processa Pharmaceuticals, Inc.'s Chief Financial Officer, Russell Skibsted, purchased 3,277 shares of common stock at $1.93 per share in an open-market transaction on June 30, 2026. This purchase increased his direct holdings to 16,689 shares. The transaction was filed in a Form ", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-47c0d4b0f826.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:21", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa (PCSA) strategy chief adds 2,106 shares in insider buy", "summary": "Patrick Lin, Chief Business-Strategy Officer at Processa Pharmaceuticals, Inc. (PCSA), made an open-market purchase of 2,106 common shares at $1.93 per share on June 30, 2026. This transaction increased his direct holdings to 13,113 shares, in addition to 1,740 shares held indire", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-9c04a893b7f5.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:21", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for Processa Pharmaceuticals Inc. It provides the date of the filing, July 1st, and is very concise in its content. The remainder of the page is filled with financial market data, indices, commodity prices, and other news ", "url": "https://ca.investing.com/news/stock-market-news/form-4-processa-pharmaceuticals-inc-for-1-july-93CH-4717006", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:39:21", "published_display": "01 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Yorke Justin W", "summary": "This document is a Form 4 statement of changes in beneficial ownership of securities for Justin W. Yorke, a director of Processa Pharmaceuticals. It indicates potential transactions or changes in his holdings of the company's stock.", "url": "https://www.moomoo.com/news/notice/307638201/processa-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-01T18:09:21", "published_display": "01 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides access to Processa Pharmaceuticals, Inc.'s financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. It details past earnings reports, highlighting net losses, cash shortfalls, and the need for additional funding, while also noting pipeline ad", "url": "https://www.tradingview.com/symbols/BOATS-PCSA/documents/", "source_name": "TradingView", "published_at": "2026-07-01T09:12:12", "published_display": "01 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOWGxKdVE3UlNzMjlBOVlJRHN6WGI5VHJJVmJZeUZyUzdwNWExUFV0a2FUZjBDZkpyZzV6RjNENDRSenhvcVY5eGx3Mmh3R1RNSU1KT1ctWi02OUpKU2dvRVF3c1dQX3oyU3ZWQlBGSkNGOGY1Z3BNdFZYZ056bEVRSkFCdjYyYzRYZl84S0h1b0R1SVZEbFVmMGZaTFdhTDhjRHVjelM0X2tVWmhWdkc3WUdjbGN1TGdNNWZSRGhwVWlueVpG?oc=5", "source_name": "Investing.com", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) director receives 203 shares from vesting", "summary": "Processa Pharmaceuticals director Neal James R received 203 shares of common stock from the vesting of a time-based service award on June 26, 2026. This transaction increased his direct holdings of common stock to 1,021 shares, while he still holds 5,249 shares of restricted stoc", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-af316ed5a0ad.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:09:45", "published_display": "01 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity", "summary": "Processa Pharmaceuticals director Geraldine Pannu reported an insider transaction involving the exercise of a derivative award for 203 shares of Common Stock on June 26, 2026, at an exercise price of $0.00. This transaction increased her direct holdings of Common Stock to 2,391 s", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-1b8f6a53defe.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:09:45", "published_display": "01 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa (NASDAQ: PCSA) director Yorke vests 203-share restricted stock award", "summary": "Processa Pharmaceuticals director Justin W. Yorke reported the vesting of a 203-share restricted stock award on June 26, 2026, receiving common stock at $0.00 per share. This transaction increases his direct holdings to 353 common shares, with additional indirect holdings and 5,2", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-22006bdbde30.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:09:45", "published_display": "01 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) director gets 203 shares from service award", "summary": "Processa Pharmaceuticals director Baluch Khoso received 203 shares of common stock from a time-based service award, converting restricted stock at an exercise price of $0.00 per share. This transaction on June 26, 2026, was a routine equity compensation event rather than a market", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-2db9af5185e7.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:09:45", "published_display": "01 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Processa Pharmaceuticals, Inc. \u2013 NASDAQ:PCSA", "summary": "The article displays the \"Price to earnings forward\" metric for Processa Pharmaceuticals, Inc. (NASDAQ:PCSA). It is presented within the context of TradingView's financial data interface, with a placeholder indicating \"No trades\" and \"Market closed\" at the time of viewing.", "url": "https://www.tradingview.com/symbols/NASDAQ-PCSA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:15:29", "published_display": "27 Jun 2026 01:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Processa Pharmaceuticals, Inc. \u2013 NASDAQ:PCSA", "summary": "This article provides financial information for Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), specifically focusing on its forward price-to-sales ratio. The content appears to be a snapshot from a financial platform like TradingView, displaying basic company information and fina", "url": "https://www.tradingview.com/symbols/NASDAQ-PCSA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:09:49", "published_display": "27 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PCSA)", "summary": "This article provides an overview of Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, upcoming earnings reports, and an analysis of its volatility and dividend", "url": "https://www.tradingview.com/symbols/NASDAQ-PCSA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:18", "published_display": "25 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCSA | Processa Pharmaceuticals, Inc. Common Executive Compensation", "summary": "This article provides detailed executive compensation information for Processa Pharmaceuticals, Inc. (PCSA), including salary, bonus, stock/option awards, and total compensation for named executives. It also offers an overview of the company, its financial data, and various analy", "url": "https://www.quiverquant.com/stock/PCSA/executive-compensation/", "source_name": "Quiver Quantitative", "published_at": "2026-06-21T17:09:22", "published_display": "21 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals | DEF 14A: Definitive information statements", "summary": "This article mentions that Processa Pharmaceuticals has filed a DEF 14A, which is a definitive information statement. Further details about the content of this filing are not provided in the snippet.", "url": "https://www.moomoo.com/news/notice/307555705/processa-pharmaceuticals-def-14a-definitive-information-statements", "source_name": "Moomoo", "published_at": "2026-06-20T14:09:49", "published_display": "20 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders to vote on Processa (NASDAQ: PCSA) equity plan and pay", "summary": "Processa Pharmaceuticals will hold its 2026 annual shareholder meeting on July 30, 2026, where shareholders will vote on key proposals including the election of six directors, an increase in the 2019 Omnibus Incentive Plan share reserve by 200,000 shares, and the ratification of ", "url": "https://www.stocktitan.net/sec-filings/PCSA/def-14a-processa-pharmaceuticals-inc-definitive-proxy-statement-1292d29f3e99.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:40:08", "published_display": "18 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Processa Pharmaceuticals Inc (PCSA) currently has no earnings forecast score available from TradingKey, which contrasts with the Biotechnology & Medical Research industry's average score of 8.13. Analysts forecast a price target of $1.00 for PCSA, with a previous quarter's EPS of", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pcsa/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:08", "published_display": "18 Jun 2026 09:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Inc", "summary": "This article provides a brief overview of Processa Pharmaceuticals Inc (PCSA), including its current stock price and market capitalization. It indicates that relevant revenue breakdown data by business and region have not yet been disclosed by the company. The page appears to be ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pcsa/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:13", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Inc (PCSA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a timeline of dividend payouts and stock splits for Processa Pharmaceuticals Inc (PCSA). It indicates that the company has distributed no dividends over the past five years and details several merger-related stock splits with specific dates and ratios. The cu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pcsa/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:13", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Inc (PCSA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Processa Pharmaceuticals Inc (PCSA), including major individual and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity wit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pcsa/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:13", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Inc (PCSA) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" score for Processa Pharmaceuticals Inc (PCSA), noting a score of 3.00 as of June 18, 2026. It details key institutional shareholders and their recent activity, including HX Entertainment Ltd with a significant ownership and incr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pcsa/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T23:09:45", "published_display": "17 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals chief business officer Lin buys $4,064 stock", "summary": "Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals, purchased 1,831 shares of the company's common stock for $4,064 at $2.22 per share. This transaction increases his direct holdings to 11,007 shares, with an additional 1,740 shares held indirectly. The pu", "url": "https://www.investing.com/news/insider-trading-news/processa-pharmaceuticals-chief-business-officer-lin-buys-4064-stock-93CH-4746372", "source_name": "Investing.com", "published_at": "2026-06-17T22:40:08", "published_display": "17 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) officer adds 1,831 shares in open-market buy", "summary": "Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals (PCSA), purchased 1,831 shares of Common Stock in an open-market transaction at $2.22 per share. Following this acquisition, Lin directly owns 11,007 shares and indirectly holds 1,740 shares through the Li", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-bf4124c0b599.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:40:33", "published_display": "16 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals CFO Russell Skibsted buys $5,891 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPWmc0MVVLQjhva0Z1b1BWbE0zSndFSFF3ODFtM2hjTzRSS1hkb21MeU9kbHRmT0RXNWdJVDdGampoQ3NCS0U4cmdZcFJkNTVCczlPS25PLUlOZWQ4aDJGam52d25ORXJqcllUR29KQmRrUGpYX04tM0IyUVFkZ1FtR0RESzdfOWpjc2RxMzJXRDU0SFVIaU40dDU0Unhhc29KVVpYWDVhQWd3ekNVb0F2ZUFzQVdnZ0Q1bVZ1akZzOWliNFZfbFNTeA?oc=5", "source_name": "Investing.com", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) CFO buys 2,654 shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQVTdJOENzVjJsUktHS2lKeW5EVEczaFVZYVVGOGVKV3F3M3NaZ083OEhkWUt5LU5rMUdpaWR2UTVBM180ZVhwbldnbzBPX0haSHctY3Q3eVhvRGJydjFfbzhMTldIMzNSZUt0ZFcwMDRJVnlMSG96amQ2WTlTM2xDc01LdmhJUWUxb1gtSHQ0VDZwSjk3ZVN3TFpjY3FCaXBkSmF2R1d1WTJ5ZU1wbDlMei1oSGFPQzV3OHpTNUJkOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) CAO buys 2,118 shares at $2.22 in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQLTRuX1NsdUlXS19qSWsyQm1OT2JaNUU4cVhDTGYwUzRKVkZtTTktRU9oMVdqTmlRY2pCd2dzYThsVEwtV2RqaEJERWxDUjdCSTdEb2s3X1BaR3MteHFUN2xBX1pfbXNBcjUzM2stZGMwR01raWQ0b0xlLTN3MTM0N2dJRlVnalpXQl9TMXl5YVBlYi1fUkVSOG1UZ1RPQzk3U282RUdOM2N3b3lIUVBhVzJlTnlrWmNXZEhEWHByWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals\u2019 pres. David Young buys $4,590 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOSDdVc0xLUEhRaUZycGxrTUJ5SjFsZ3MzbXltQmRUZExrNmc1Uld6X0RGVFliQ2VhSHVJQm5VT2xfM2FDaEMtSUg4YVRSbTRQOVlLZFloSHpmMlZPLUtuSEpIRUNHSmJoYXZpWm9DT24zYWltcHBmUnkya3JEOTAtYkpDX3VRTWxpYVpZUVRkNEItSS1LcWlpd1dYNUgtOXlZQlJSYjJKaFFXS3dRaGlPR0FuT09jdHhIQTk4Rm85TzJVU1U?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa (PCSA) CEO adds 1,843 shares and corrects prior Form 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQT1JwSWhQX2RzZzZHQkNEdDQ1aXZrTU00cUJJcjBMVHdKVmUtWWRrV1huSjBfNlZhUGI2bkhxTjVyWjVCZ0lac2tHczZOMXhiWV9kbnVrN1VndXVWRUY1UkJwVHdiRDBFbmx0LXZuWjdVVEd2djNHcmRzeWo3U2lmRS01ZFFlZUd0S0hFanB2SWlmRlQ4WXFPTDNobEU3Wk1FS2p3b2JfQjVSV19SRmJ4b01obTNLa1lhMVlsc1ZTcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sian Bigora, Processa CDO, buys $5,341 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQU1RQd3dVWDFmX0x1ckQycFJabURtSDk3Zk9Vb0xCWHRiSmZVZjQ5N2FLdVFfVTUwM1Z2RjExZnVrQlNTWEtzRVZGRDZncHBKVHRmam1qUWFkMmEyY1JhMzlPekFtV09oTW81WDdqcWtyV2FQTFAwNUQzandkdWVhQkJ0b0pnc0h6Wi1tMUZuUk9ab295OXB0NXZVUFdKMjBQU2NyNGRJb05RZTJp?oc=5", "source_name": "Investing.com", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Processa (PCSA) strategy chief buys 1,369 shares at $2.97", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxON3dmcDNiNmJnRm84NC04QkJYTjIwMmFybjBPN01TWkZJWjhqVXdQSjFQY2cyaDdwYkYtWEtORXVjLTNGOWNKUm5yRDUzYWh6YnRDR0gxdG1DNnB4QTBJT3FWTUVMYUgxS2xpVmxsMjFpMU01Z2xaTkZTQnQwbTJSN1Y0VVFtaURCbTBNb2xDTFVpYmdQbFJENW5KcDFFelpmYnZlTWJvRkdpUXJvdGQ5QkJ2aVA5R1FYd3Z3R1lXbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Did Processa Pharmaceuticals Stock Surge 160% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNX0t6MEFVYWFVMVRwRXBtaG1Za1dOZ0dDa09sVUo5SUxQT2xtMExQU2U2WHlRVTl4ak5vSnlDVEphSUs5WHFkcWhpTDNodzhIdHBzOGhKWmpqYmU4VkRRR1hMc3hXV3c3SkFYMzdaNWE0ckk3MWY3THZtWVhJMERfT0pVdFI0MFFWOXI2S21pVlJrdzUzRzJsTGpSeXFhei1JcGdoYldIVjA0alB5NHR2X1BaYlNiNkdhSGc?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPeDZPLTdWSXo5aHFadkN2a29oSWprcmt4WVYwTksxSXFaUGFUV2xNLVNjWDI3d0t5aUIydk1WV2RfV3lOckZQS0dWU3k5X0hRLVAyMHRZbXJmN0VIdVhmZnNLLXJBUGJ4bVdsVGJzYTAyQ1ZvYzdRVURnVzRBSFdicEVDMjRySmNlZnVxLW84djBqUjE5dmVFZE81cVBRd25mWjBMcWZ2TEozZkp2TU5wSFk5bnp0N0EtSkE?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals stock soars after cancer drug shows promising results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNVW5UN3dkTUI3a3EzNTJBM2R4VmNMdXJNbDRMRzdfa0N3NjFRb0NFWkhOMGw2cjJ3Rk9aT0RMbU5LLWpPSnkyQ1ZPdS1XY3BncVR5amhlMTFSTGFGb3N5Ri1RQnM5Vm5VQkhPVGpHcjBEdnlEdmxfY09ZMzY5ZnpzT2NzNGVDNEt1UWhQNVBncHNzVGVlcno3OTBjcGw4WmwybU5acXo5YjF2ajdiYzB6QTFTTk5ZbnRVcXhwVnV1MWpkd0ZfeDdCY2h4eUk0LUdpcU1VTzRuOA?oc=5", "source_name": "Investing.com", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNZWNoa21Da3VLY3Z4RzF2akNLTlJuXzl3VVlQRmxlRXFJX3ZrX2gtRU9ibkNSV1BSM1pYQWRoU3Z2VjlmcUVSY3dNeTNoRUhENmpMYWtLeUdvZ2V3ZjFvUWF2cjN6ZHNFRFNMTGJEN0JPX0dDZWFyak1EN0ZTbkxJYVFVZWFCMUYtYkx6SmVsUzk4blhSZkdrMklB?oc=5", "source_name": "Market source", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals announces 1-for-25 reverse stock split effective this week", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNZGJIVUhTalNjaWs4cWV6ZHA1SmlkTlR0cjdKQjZEOXFubTVhX3FBWVhPX1l2eE9wYWVrQkVzMFJCNzhjZmh6WHE2elJUemF4OXoweVBnTktWaVBsaHI1aFdaWjc0djdlTmk5SVNDb0ozZVVHcTRWVGpqNWNwcnd3RVNNeUlfbjZjVHhIZDE4SFZJcnRxRVk4cl8tbFprd0dsTFJoZThUV1JvMHV3LTZRUzd1VkxTeHFVRkgzSHh5bXRhdFRmYWZyZmZPMHJ0WDlOYjhN?oc=5", "source_name": "Investing.com", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCSA Stock Price and Chart \u2014 NASDAQ:PCSA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE53aFowRHh0cjhPUGlfWXVLYlRocG1heEFlaXNrelVPNG9QaWN1QjNkYm92dHNydW90OXVRejNfNkotNWNmTXFCT3ZWdFpPbTlCSktkUG9PaWZpRXhv?oc=5", "source_name": "TradingView", "published_at": "2020-09-27T00:57:45+00:00", "published_display": "27 Sep 2020 00:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Raises $6.88 Million From Private Placements", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPNDcwNl9QQmVKNll1LTIzQVM4SlN6T1ppcWRwZWZleG1tWUhkNXhuWHlnTWhPN3BRQUd0ZUFxUHBpejdlOEtqYWl4VUF4QWpDLXUwNkhidjAwMW5nQlNMWnA2TG9oQnNDQzcwcDR1aUlMdmgxWV9VRE1oWk5MNXE5TXdMU2hndGZOV0pBS0RldVVVZmNZbXZtaE9PVjllU2xqdkxsVFNiQ1Nkb09Ua25NOWFTREkwbG9iS1BjWTRXcTZRZw?oc=5", "source_name": "PR Newswire", "published_at": "2018-06-01T07:00:00+00:00", "published_display": "01 Jun 2018 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Processa Pharma (PCSA) Stock Analysis Report | Financials & Insights", "summary": "This report provides a stock analysis for Processa Pharma (PCSA), a clinical-stage biopharmaceutical company focusing on Next Generation Chemotherapy oncology drug products. It covers the company's general information, how it's graded based on various financial metrics, peer comp", "url": "https://es.benzinga.com/quote/PCSA/report", "source_name": "Benzinga Espa\u00f1a", "published_at": "2026-07-04T07:11:56", "published_display": "04 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL", "summary": "This article is a statement of changes in beneficial ownership of securities for Officer SKIBSTED RUSSELL at Processa Pharmaceuticals. It indicates a filing of Form Type 4, which is used to report changes in ownership of company stock by insiders. The article details the specific", "url": "https://www.moomoo.com/news/notice/307647847/processa-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-03T19:12:07", "published_display": "03 Jul 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PROCESSA PHARMACEUTICALS INC. For: Jun 03 Filed: Jun 06", "summary": "This document, filed by PROCESSA PHARMACEUTICALS INC. on June 6 for the date June 3, is a statement of changes in beneficial ownership of securities. It specifically details changes for Officer Ng George K.", "url": "https://www.moomoo.com/news/notice/307647870/processa-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-03T19:12:07", "published_display": "03 Jul 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Lin Patrick", "summary": "This document reports a statement of changes in beneficial ownership of securities for Officer Lin Patrick of Processa Pharmaceuticals. It is filed as a Form 4, indicating transactions related to his holdings in the company.", "url": "https://www.moomoo.com/news/notice/307647882/processa-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-02T18:12:09", "published_display": "02 Jul 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) director buys 2,531 shares in open market", "summary": "Processa Pharmaceuticals (PCSA) director David Young purchased 2,531 shares of common stock at $1.93 per share in an open-market transaction on June 30, 2026. This acquisition increases his direct holdings to 21,729 shares. Young also reported indirect ownership through several e", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-0a411d1abcf2.html", "source_name": "Stock Titan", "published_at": "2026-07-02T04:39:21", "published_display": "02 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock By Investing.com", "summary": "Processa Pharmaceuticals CEO George Ng recently acquired 3,057 shares of the company's common stock for $5,900. This transaction increases his direct holdings to 15,492 shares, in addition to indirect holdings. The purchase occurred while PCSA stock is trading near its 52-week lo", "url": "https://ca.investing.com/news/stock-market-news/processa-pharmaceuticals-ceo-george-ng-acquires-5900-in-stock-93CH-4716992", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:39:21", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) CEO adds 3,057 shares in open-market buy", "summary": "Processa Pharmaceuticals (PCSA) CEO George K. Ng purchased 3,057 shares of Common Stock in an open-market transaction at $1.93 per share on July 1, 2026. Following this transaction, Ng directly owns 15,492 shares, with additional indirect holdings through related entities. The pu", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-6e53c2c846cf.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:21", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider purchase: Processa (NASDAQ: PCSA) CAO adds 2,436 shares in open-market buy", "summary": "Processa Pharmaceuticals' Chief Administrative Officer Guy Wendy recently purchased 2,436 shares of common stock at $1.93 per share in an open-market transaction. Following this purchase, Wendy directly holds 14,394 shares and indirectly owns 333 shares through CorLyst, LLC. This", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-854481868d0c.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:21", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CFO of Processa (NASDAQ: PCSA) adds 3,277 shares in open-market buy", "summary": "Processa Pharmaceuticals, Inc.'s Chief Financial Officer, Russell Skibsted, purchased 3,277 shares of common stock at $1.93 per share in an open-market transaction on June 30, 2026. This purchase increased his direct holdings to 16,689 shares. The transaction was filed in a Form ", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-47c0d4b0f826.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:21", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa (PCSA) strategy chief adds 2,106 shares in insider buy", "summary": "Patrick Lin, Chief Business-Strategy Officer at Processa Pharmaceuticals, Inc. (PCSA), made an open-market purchase of 2,106 common shares at $1.93 per share on June 30, 2026. This transaction increased his direct holdings to 13,113 shares, in addition to 1,740 shares held indire", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-9c04a893b7f5.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:21", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for Processa Pharmaceuticals Inc. It provides the date of the filing, July 1st, and is very concise in its content. The remainder of the page is filled with financial market data, indices, commodity prices, and other news ", "url": "https://ca.investing.com/news/stock-market-news/form-4-processa-pharmaceuticals-inc-for-1-july-93CH-4717006", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:39:21", "published_display": "01 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Yorke Justin W", "summary": "This document is a Form 4 statement of changes in beneficial ownership of securities for Justin W. Yorke, a director of Processa Pharmaceuticals. It indicates potential transactions or changes in his holdings of the company's stock.", "url": "https://www.moomoo.com/news/notice/307638201/processa-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-01T18:09:21", "published_display": "01 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides access to Processa Pharmaceuticals, Inc.'s financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. It details past earnings reports, highlighting net losses, cash shortfalls, and the need for additional funding, while also noting pipeline ad", "url": "https://www.tradingview.com/symbols/BOATS-PCSA/documents/", "source_name": "TradingView", "published_at": "2026-07-01T09:12:12", "published_display": "01 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOWGxKdVE3UlNzMjlBOVlJRHN6WGI5VHJJVmJZeUZyUzdwNWExUFV0a2FUZjBDZkpyZzV6RjNENDRSenhvcVY5eGx3Mmh3R1RNSU1KT1ctWi02OUpKU2dvRVF3c1dQX3oyU3ZWQlBGSkNGOGY1Z3BNdFZYZ056bEVRSkFCdjYyYzRYZl84S0h1b0R1SVZEbFVmMGZaTFdhTDhjRHVjelM0X2tVWmhWdkc3WUdjbGN1TGdNNWZSRGhwVWlueVpG?oc=5", "source_name": "Investing.com", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) director receives 203 shares from vesting", "summary": "Processa Pharmaceuticals director Neal James R received 203 shares of common stock from the vesting of a time-based service award on June 26, 2026. This transaction increased his direct holdings of common stock to 1,021 shares, while he still holds 5,249 shares of restricted stoc", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-af316ed5a0ad.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:09:45", "published_display": "01 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity", "summary": "Processa Pharmaceuticals director Geraldine Pannu reported an insider transaction involving the exercise of a derivative award for 203 shares of Common Stock on June 26, 2026, at an exercise price of $0.00. This transaction increased her direct holdings of Common Stock to 2,391 s", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-1b8f6a53defe.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:09:45", "published_display": "01 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa (NASDAQ: PCSA) director Yorke vests 203-share restricted stock award", "summary": "Processa Pharmaceuticals director Justin W. Yorke reported the vesting of a 203-share restricted stock award on June 26, 2026, receiving common stock at $0.00 per share. This transaction increases his direct holdings to 353 common shares, with additional indirect holdings and 5,2", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-22006bdbde30.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:09:45", "published_display": "01 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) director gets 203 shares from service award", "summary": "Processa Pharmaceuticals director Baluch Khoso received 203 shares of common stock from a time-based service award, converting restricted stock at an exercise price of $0.00 per share. This transaction on June 26, 2026, was a routine equity compensation event rather than a market", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-2db9af5185e7.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:09:45", "published_display": "01 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Processa Pharmaceuticals, Inc. \u2013 NASDAQ:PCSA", "summary": "The article displays the \"Price to earnings forward\" metric for Processa Pharmaceuticals, Inc. (NASDAQ:PCSA). It is presented within the context of TradingView's financial data interface, with a placeholder indicating \"No trades\" and \"Market closed\" at the time of viewing.", "url": "https://www.tradingview.com/symbols/NASDAQ-PCSA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:15:29", "published_display": "27 Jun 2026 01:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Processa Pharmaceuticals, Inc. \u2013 NASDAQ:PCSA", "summary": "This article provides financial information for Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), specifically focusing on its forward price-to-sales ratio. The content appears to be a snapshot from a financial platform like TradingView, displaying basic company information and fina", "url": "https://www.tradingview.com/symbols/NASDAQ-PCSA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:09:49", "published_display": "27 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PCSA)", "summary": "This article provides an overview of Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, upcoming earnings reports, and an analysis of its volatility and dividend", "url": "https://www.tradingview.com/symbols/NASDAQ-PCSA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:18", "published_display": "25 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCSA | Processa Pharmaceuticals, Inc. Common Executive Compensation", "summary": "This article provides detailed executive compensation information for Processa Pharmaceuticals, Inc. (PCSA), including salary, bonus, stock/option awards, and total compensation for named executives. It also offers an overview of the company, its financial data, and various analy", "url": "https://www.quiverquant.com/stock/PCSA/executive-compensation/", "source_name": "Quiver Quantitative", "published_at": "2026-06-21T17:09:22", "published_display": "21 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals | DEF 14A: Definitive information statements", "summary": "This article mentions that Processa Pharmaceuticals has filed a DEF 14A, which is a definitive information statement. Further details about the content of this filing are not provided in the snippet.", "url": "https://www.moomoo.com/news/notice/307555705/processa-pharmaceuticals-def-14a-definitive-information-statements", "source_name": "Moomoo", "published_at": "2026-06-20T14:09:49", "published_display": "20 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders to vote on Processa (NASDAQ: PCSA) equity plan and pay", "summary": "Processa Pharmaceuticals will hold its 2026 annual shareholder meeting on July 30, 2026, where shareholders will vote on key proposals including the election of six directors, an increase in the 2019 Omnibus Incentive Plan share reserve by 200,000 shares, and the ratification of ", "url": "https://www.stocktitan.net/sec-filings/PCSA/def-14a-processa-pharmaceuticals-inc-definitive-proxy-statement-1292d29f3e99.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:40:08", "published_display": "18 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Processa Pharmaceuticals Inc (PCSA) currently has no earnings forecast score available from TradingKey, which contrasts with the Biotechnology & Medical Research industry's average score of 8.13. Analysts forecast a price target of $1.00 for PCSA, with a previous quarter's EPS of", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pcsa/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:08", "published_display": "18 Jun 2026 09:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Inc", "summary": "This article provides a brief overview of Processa Pharmaceuticals Inc (PCSA), including its current stock price and market capitalization. It indicates that relevant revenue breakdown data by business and region have not yet been disclosed by the company. The page appears to be ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pcsa/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:13", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Inc (PCSA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a timeline of dividend payouts and stock splits for Processa Pharmaceuticals Inc (PCSA). It indicates that the company has distributed no dividends over the past five years and details several merger-related stock splits with specific dates and ratios. The cu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pcsa/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:13", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Inc (PCSA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Processa Pharmaceuticals Inc (PCSA), including major individual and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity wit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pcsa/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:13", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Inc (PCSA) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" score for Processa Pharmaceuticals Inc (PCSA), noting a score of 3.00 as of June 18, 2026. It details key institutional shareholders and their recent activity, including HX Entertainment Ltd with a significant ownership and incr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pcsa/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T23:09:45", "published_display": "17 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals chief business officer Lin buys $4,064 stock", "summary": "Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals, purchased 1,831 shares of the company's common stock for $4,064 at $2.22 per share. This transaction increases his direct holdings to 11,007 shares, with an additional 1,740 shares held indirectly. The pu", "url": "https://www.investing.com/news/insider-trading-news/processa-pharmaceuticals-chief-business-officer-lin-buys-4064-stock-93CH-4746372", "source_name": "Investing.com", "published_at": "2026-06-17T22:40:08", "published_display": "17 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) officer adds 1,831 shares in open-market buy", "summary": "Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals (PCSA), purchased 1,831 shares of Common Stock in an open-market transaction at $2.22 per share. Following this acquisition, Lin directly owns 11,007 shares and indirectly holds 1,740 shares through the Li", "url": "https://www.stocktitan.net/sec-filings/PCSA/form-4-processa-pharmaceuticals-inc-insider-trading-activity-bf4124c0b599.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:40:33", "published_display": "16 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals CFO Russell Skibsted buys $5,891 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPWmc0MVVLQjhva0Z1b1BWbE0zSndFSFF3ODFtM2hjTzRSS1hkb21MeU9kbHRmT0RXNWdJVDdGampoQ3NCS0U4cmdZcFJkNTVCczlPS25PLUlOZWQ4aDJGam52d25ORXJqcllUR29KQmRrUGpYX04tM0IyUVFkZ1FtR0RESzdfOWpjc2RxMzJXRDU0SFVIaU40dDU0Unhhc29KVVpYWDVhQWd3ekNVb0F2ZUFzQVdnZ0Q1bVZ1akZzOWliNFZfbFNTeA?oc=5", "source_name": "Investing.com", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) CFO buys 2,654 shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQVTdJOENzVjJsUktHS2lKeW5EVEczaFVZYVVGOGVKV3F3M3NaZ083OEhkWUt5LU5rMUdpaWR2UTVBM180ZVhwbldnbzBPX0haSHctY3Q3eVhvRGJydjFfbzhMTldIMzNSZUt0ZFcwMDRJVnlMSG96amQ2WTlTM2xDc01LdmhJUWUxb1gtSHQ0VDZwSjk3ZVN3TFpjY3FCaXBkSmF2R1d1WTJ5ZU1wbDlMei1oSGFPQzV3OHpTNUJkOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals (PCSA) CAO buys 2,118 shares at $2.22 in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQLTRuX1NsdUlXS19qSWsyQm1OT2JaNUU4cVhDTGYwUzRKVkZtTTktRU9oMVdqTmlRY2pCd2dzYThsVEwtV2RqaEJERWxDUjdCSTdEb2s3X1BaR3MteHFUN2xBX1pfbXNBcjUzM2stZGMwR01raWQ0b0xlLTN3MTM0N2dJRlVnalpXQl9TMXl5YVBlYi1fUkVSOG1UZ1RPQzk3U282RUdOM2N3b3lIUVBhVzJlTnlrWmNXZEhEWHByWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals\u2019 pres. David Young buys $4,590 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOSDdVc0xLUEhRaUZycGxrTUJ5SjFsZ3MzbXltQmRUZExrNmc1Uld6X0RGVFliQ2VhSHVJQm5VT2xfM2FDaEMtSUg4YVRSbTRQOVlLZFloSHpmMlZPLUtuSEpIRUNHSmJoYXZpWm9DT24zYWltcHBmUnkya3JEOTAtYkpDX3VRTWxpYVpZUVRkNEItSS1LcWlpd1dYNUgtOXlZQlJSYjJKaFFXS3dRaGlPR0FuT09jdHhIQTk4Rm85TzJVU1U?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa (PCSA) CEO adds 1,843 shares and corrects prior Form 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQT1JwSWhQX2RzZzZHQkNEdDQ1aXZrTU00cUJJcjBMVHdKVmUtWWRrV1huSjBfNlZhUGI2bkhxTjVyWjVCZ0lac2tHczZOMXhiWV9kbnVrN1VndXVWRUY1UkJwVHdiRDBFbmx0LXZuWjdVVEd2djNHcmRzeWo3U2lmRS01ZFFlZUd0S0hFanB2SWlmRlQ4WXFPTDNobEU3Wk1FS2p3b2JfQjVSV19SRmJ4b01obTNLa1lhMVlsc1ZTcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sian Bigora, Processa CDO, buys $5,341 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQU1RQd3dVWDFmX0x1ckQycFJabURtSDk3Zk9Vb0xCWHRiSmZVZjQ5N2FLdVFfVTUwM1Z2RjExZnVrQlNTWEtzRVZGRDZncHBKVHRmam1qUWFkMmEyY1JhMzlPekFtV09oTW81WDdqcWtyV2FQTFAwNUQzandkdWVhQkJ0b0pnc0h6Wi1tMUZuUk9ab295OXB0NXZVUFdKMjBQU2NyNGRJb05RZTJp?oc=5", "source_name": "Investing.com", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa (PCSA) strategy chief buys 1,369 shares at $2.97", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxON3dmcDNiNmJnRm84NC04QkJYTjIwMmFybjBPN01TWkZJWjhqVXdQSjFQY2cyaDdwYkYtWEtORXVjLTNGOWNKUm5yRDUzYWh6YnRDR0gxdG1DNnB4QTBJT3FWTUVMYUgxS2xpVmxsMjFpMU01Z2xaTkZTQnQwbTJSN1Y0VVFtaURCbTBNb2xDTFVpYmdQbFJENW5KcDFFelpmYnZlTWJvRkdpUXJvdGQ5QkJ2aVA5R1FYd3Z3R1lXbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Processa Pharmaceuticals Stock Surge 160% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNX0t6MEFVYWFVMVRwRXBtaG1Za1dOZ0dDa09sVUo5SUxQT2xtMExQU2U2WHlRVTl4ak5vSnlDVEphSUs5WHFkcWhpTDNodzhIdHBzOGhKWmpqYmU4VkRRR1hMc3hXV3c3SkFYMzdaNWE0ckk3MWY3THZtWVhJMERfT0pVdFI0MFFWOXI2S21pVlJrdzUzRzJsTGpSeXFhei1JcGdoYldIVjA0alB5NHR2X1BaYlNiNkdhSGc?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPeDZPLTdWSXo5aHFadkN2a29oSWprcmt4WVYwTksxSXFaUGFUV2xNLVNjWDI3d0t5aUIydk1WV2RfV3lOckZQS0dWU3k5X0hRLVAyMHRZbXJmN0VIdVhmZnNLLXJBUGJ4bVdsVGJzYTAyQ1ZvYzdRVURnVzRBSFdicEVDMjRySmNlZnVxLW84djBqUjE5dmVFZE81cVBRd25mWjBMcWZ2TEozZkp2TU5wSFk5bnp0N0EtSkE?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals stock soars after cancer drug shows promising results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNVW5UN3dkTUI3a3EzNTJBM2R4VmNMdXJNbDRMRzdfa0N3NjFRb0NFWkhOMGw2cjJ3Rk9aT0RMbU5LLWpPSnkyQ1ZPdS1XY3BncVR5amhlMTFSTGFGb3N5Ri1RQnM5Vm5VQkhPVGpHcjBEdnlEdmxfY09ZMzY5ZnpzT2NzNGVDNEt1UWhQNVBncHNzVGVlcno3OTBjcGw4WmwybU5acXo5YjF2ajdiYzB6QTFTTk5ZbnRVcXhwVnV1MWpkd0ZfeDdCY2h4eUk0LUdpcU1VTzRuOA?oc=5", "source_name": "Investing.com", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNZWNoa21Da3VLY3Z4RzF2akNLTlJuXzl3VVlQRmxlRXFJX3ZrX2gtRU9ibkNSV1BSM1pYQWRoU3Z2VjlmcUVSY3dNeTNoRUhENmpMYWtLeUdvZ2V3ZjFvUWF2cjN6ZHNFRFNMTGJEN0JPX0dDZWFyak1EN0ZTbkxJYVFVZWFCMUYtYkx6SmVsUzk4blhSZkdrMklB?oc=5", "source_name": "Market source", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals announces 1-for-25 reverse stock split effective this week", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNZGJIVUhTalNjaWs4cWV6ZHA1SmlkTlR0cjdKQjZEOXFubTVhX3FBWVhPX1l2eE9wYWVrQkVzMFJCNzhjZmh6WHE2elJUemF4OXoweVBnTktWaVBsaHI1aFdaWjc0djdlTmk5SVNDb0ozZVVHcTRWVGpqNWNwcnd3RVNNeUlfbjZjVHhIZDE4SFZJcnRxRVk4cl8tbFprd0dsTFJoZThUV1JvMHV3LTZRUzd1VkxTeHFVRkgzSHh5bXRhdFRmYWZyZmZPMHJ0WDlOYjhN?oc=5", "source_name": "Investing.com", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCSA Stock Price and Chart \u2014 NASDAQ:PCSA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE53aFowRHh0cjhPUGlfWXVLYlRocG1heEFlaXNrelVPNG9QaWN1QjNkYm92dHNydW90OXVRejNfNkotNWNmTXFCT3ZWdFpPbTlCSktkUG9PaWZpRXhv?oc=5", "source_name": "TradingView", "published_at": "2020-09-27T00:57:45+00:00", "published_display": "27 Sep 2020 00:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Processa Pharmaceuticals Raises $6.88 Million From Private Placements", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPNDcwNl9QQmVKNll1LTIzQVM4SlN6T1ppcWRwZWZleG1tWUhkNXhuWHlnTWhPN3BRQUd0ZUFxUHBpejdlOEtqYWl4VUF4QWpDLXUwNkhidjAwMW5nQlNMWnA2TG9oQnNDQzcwcDR1aUlMdmgxWV9VRE1oWk5MNXE5TXdMU2hndGZOV0pBS0RldVVVZmNZbXZtaE9PVjllU2xqdkxsVFNiQ1Nkb09Ua25NOWFTREkwbG9iS1BjWTRXcTZRZw?oc=5", "source_name": "PR Newswire", "published_at": "2018-06-01T07:00:00+00:00", "published_display": "01 Jun 2018 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 54, "sentiment_summary": {"positive": 11, "negative": 3, "neutral": 40, "score": 52, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 19.25, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 2.31, "latest_week": "2026-07-17", "one_week_move": 6.9, "four_week_move": 9.0, "twelve_week_move": -22.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.032571, "market_dynamics_buy_signal": false, "relative_strength": -51.25552, "fair_value_gap": -95.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.3742, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.9% over one week, +9.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 15}, {"label": "Market source", "count": 7}, {"label": "Investing.com", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "Moomoo", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "Investing.com Canada", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 3}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+6.9% over one week, +9.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Processa Pharma (PCSA) Stock Analysis Report | Financials & Insights"}], "updated_at": "2026-07-21T22:56:06.948943+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}